209 related articles for article (PubMed ID: 21393426)
1. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
2. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M
Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242
[TBL] [Abstract][Full Text] [Related]
3. CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Liu H; Peng F; Liu Z; Jiang F; Li L; Gao S; Wang G; Song J; Ruan E; Shao Z; Fu R
Int J Oncol; 2017 Feb; 50(2):631-639. PubMed ID: 28035364
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Jia X; Cheng J; Shen Z; Shao Z; Liu G
Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
[TBL] [Abstract][Full Text] [Related]
5. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
Lan YC; Chang CL; Sung MT; Yin PH; Hsu CC; Wang KC; Lee HC; Tseng LM; Chi CW
Anticancer Res; 2013 Sep; 33(9):3807-14. PubMed ID: 24023313
[TBL] [Abstract][Full Text] [Related]
7. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Insalaco L; Di Gaudio F; Terrasi M; Amodeo V; Caruso S; Corsini LR; Fanale D; Margarese N; Santini D; Bazan V; Russo A
J Cell Mol Med; 2012 Sep; 16(9):2186-95. PubMed ID: 22260151
[TBL] [Abstract][Full Text] [Related]
8. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
[TBL] [Abstract][Full Text] [Related]
10. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
[TBL] [Abstract][Full Text] [Related]
11. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Denoyelle C; Hong L; Vannier JP; Soria J; Soria C
Br J Cancer; 2003 May; 88(10):1631-40. PubMed ID: 12771933
[TBL] [Abstract][Full Text] [Related]
12. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US
PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1.
Kijima T; Koga F; Fujii Y; Yoshida S; Tatokoro M; Kihara K
PLoS One; 2013; 8(5):e64615. PubMed ID: 23741352
[TBL] [Abstract][Full Text] [Related]
14. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
15. Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia.
Lee HY; Chung JW; Youn SW; Kim JY; Park KW; Koo BK; Oh BH; Park YB; Chaqour B; Walsh K; Kim HS
Circ Res; 2007 Feb; 100(3):372-80. PubMed ID: 17234971
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
19. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
Wolfe AR; Debeb BG; Lacerda L; Larson R; Bambhroliya A; Huang X; Bertucci F; Finetti P; Birnbaum D; Van Laere S; Diagaradjan P; Ruffell B; Trenton NJ; Chu K; Hittelman W; Diehl M; Levental I; Ueno NT; Woodward WA
Breast Cancer Res Treat; 2015 Dec; 154(3):495-508. PubMed ID: 26590814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]